Key result
Circulating levels of sAng-2 correlated with tumor progression and patient survival in melanoma patients.
Why the study?
Does circulating soluble Ang-2 (sAng-2) correlate with disease progression and survival in patients with malignant melanoma?
Observational (n=98)
Does circulating soluble Ang-2 (sAng-2) correlate with disease progression and survival in patients with malignant melanoma?
Circulating soluble Ang-2 is a promising biomarker for melanoma progression and survival, outperforming the established marker S100beta.
Answers are grounded in this paper and cite their sources.
sAng-2 may inform melanoma prognosis; hypothesis-generating and should not yet change practice.
PURPOSE: The blood vessel-destabilizing Tie2 ligand angiopoietin-2 (Ang-2) acts in concert with the vascular endothelial growth factor/vascular endothelial growth factor receptor system to control vessel assembly during tumor progression. We hypothesized that circulating soluble Ang-2 (sAng-2) may be involved in melanoma progression. EXPERIMENTAL DESIGN: Serum samples (n=98) from melanoma patients (American Joint Committee on Cancer stages I-IV), biopsies of corresponding patients, and human melanoma cell lines were analyzed for expression of Ang-2 and S100beta. Multiple sera of a subcohort of 33 patients were tested during progression from stage III to IV. Small interfering RNA-based loss-of-function experiments were done to assess effects of Ang-2 on melanoma cells. RESULTS: Circulating levels of sAng-2 correlate with tumor progression in melanoma patients (P<0.0001) and patient survival (P=0.007). Analysis of serum samples during the transition from stage III to IV identified an increase of sAng-2 up to 400%. Comparative analyses revealed a 56% superiority of sAng-2 as predictive marker over the established marker S100beta. Immunohistochemistry and reverse transcription-PCR confirmed the prominent expression of Ang-2 by tumor-associated endothelial cells but identified Ang-2 also as a secreted product of melanoma cells themselves. Corresponding cellular experiments revealed that human melanoma-isolated tumor cells were Tie2 positive and that Ang-2 acted as an autocrine regulator of melanoma cell migration and invasion. CONCLUSIONS: The experiments establish sAng-2 as a biomarker of melanoma progression and metastasis correlating with tumor load and overall survival. The identification of an autocrine angiopoietin/Tie loop controlling melanoma migration and invasion warrants further functional experiments and validate the angiopoietin/Tie system as a promising therapeutic target for human melanomas.
No takes yet. Share an insight, caveat, or question.
Helfrich et al. (2009) conducted an observational in Malignant Melanoma (n=98). Circulating soluble Ang-2 (sAng-2) levels was evaluated on Tumor progression (p=<0.0001). Circulating levels of sAng-2 correlated with tumor progression and patient survival in melanoma patients.
Synapse has enriched 10 related papers. Consider them for comparative context: